InsiderClue
Insiders · Profile

Posard Matthew L.

Director at HALOZYME THERAPEUTICS · Director at Nautilus Biotechnology · Sr VP & General Manager at ILLUMINA. Filing since 11 Apr 2013. CIK 0001543792

HALO HALOZYME THERAPEUTICS, INC. Director · 10 trades NAUT Nautilus Biotechnology, Inc. Director · 2 trades ILMN ILLUMINA, INC. Sr VP & General Manager · 2 trades
Company
Date
Role
Action
Shares
Amount
Of holding
HALO HALOZYME THERAPEUTICS, INC.
1 Oct 2026
Director
Sold on a plan
5,230
$567.66K
8.9%
HALO HALOZYME THERAPEUTICS, INC.
16 Sep 2026
Director
Sold on a plan
18,996
$2.05M
24.4%
HALO HALOZYME THERAPEUTICS, INC.
14 Aug 2024
Director
Sold at will
9,881
$570.13K
12.4%
HALO HALOZYME THERAPEUTICS, INC.
13 Aug 2024
Director
Sold at will
10,000
$561.93K
11.1%
HALO HALOZYME THERAPEUTICS, INC.
12 Aug 2024
Director
Sold at will
10,000
$557.23K
10.0%
HALO HALOZYME THERAPEUTICS, INC.
12 Jun 2024
Director
Sold at will
10,000
$506.19K
9.1%
HALO HALOZYME THERAPEUTICS, INC.
11 Jun 2024
Director
Sold at will
10,000
$500.11K
8.4%
HALO HALOZYME THERAPEUTICS, INC.
6 Dec 2022
Director
Sold, plan not stated
10,000
$561.18K
8.7%
HALO HALOZYME THERAPEUTICS, INC.
5 Dec 2022
Director
Sold, plan not stated
10,000
$557.37K
8.0%
HALO HALOZYME THERAPEUTICS, INC.
2 Dec 2022
Director
Sold, plan not stated
10,000
$588.00K
7.4%
NAUT Nautilus Biotechnology, Inc.
1 Dec 2021
Director
Bought
30,000
$134.11K
150%
NAUT Nautilus Biotechnology, Inc.
30 Nov 2021
Director
Bought
20,000
$91.40K
opened
ILMN ILLUMINA, INC.
30 May 2013
Sr VP & General Manager
Sold, plan not stated
2,836
$200.79K
8.4%
ILMN ILLUMINA, INC.
11 Apr 2013
Sr VP & General Manager
Sold, plan not stated
48,232
$2.80M
61.0%
14 decisions on file.